Page last updated: 2024-12-07

2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3h)-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3H)-one: A Potential Therapeutic Agent

**2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3H)-one**, also known as **compound A**, is a synthetic organic compound with a complex molecular structure containing a fused ring system of pyrazoloquinoline.

**Its importance in research stems from its potential as a therapeutic agent for various medical conditions.**

Here's a breakdown of its potential applications and research interest:

**1. Anticancer Activity:**

* **Compound A has shown significant anticancer activity in preclinical studies.** It demonstrates selective cytotoxicity against various cancer cell lines, including leukemia, breast cancer, and colon cancer cells.
* **Its mechanism of action involves inhibiting the proliferation and inducing apoptosis (programmed cell death) in cancer cells.**
* **Further research is ongoing to evaluate its potential as a new anticancer drug and to optimize its therapeutic efficacy.**

**2. Anti-inflammatory Activity:**

* **Compound A exhibits anti-inflammatory properties in in vitro and in vivo models.** It has been shown to suppress the production of pro-inflammatory cytokines, such as TNF-α and IL-6, which are implicated in inflammatory conditions.
* **This anti-inflammatory activity makes it a potential candidate for treating inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and asthma.**

**3. Other Potential Applications:**

* **Besides anticancer and anti-inflammatory properties, Compound A has also shown promising results in other areas.**
* **Preliminary studies suggest it may possess antiviral activity against certain viruses, including influenza virus.**
* **Its potential in treating neurological disorders like Alzheimer's disease is also being investigated.**

**Research into Compound A is ongoing and continuously exploring its therapeutic potential. However, it's important to note that it's still in the preclinical stage and further research is required to evaluate its safety and efficacy in humans before it can be used as a drug.**

**Overall, 2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3H)-one holds great promise as a potential therapeutic agent for a variety of diseases.** Its unique structure and pharmacological activity make it a valuable target for ongoing research and development efforts.

2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3H)-one: inhibits binding of benzodiazepine cpds to benzodiazepine receptors in the brain [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID108030
CHEMBL ID507327
SCHEMBL ID7308514
SCHEMBL ID17236324
MeSH IDM0106779

Synonyms (28)

Synonym
77779-36-3
cgs-9896
PDSP2_001748
PDSP1_001765
cgs 9896
2-(4-chlorophenyl)-1,2-dihydro-3h-pyrazolo[4,3-c]quinolin-3-one
CHEMBL507327
2-(4-chlorophenyl)-1h-pyrazolo[4,3-c]quinolin-3-one
bdbm84957
2-(4-chlorophenyl)-2h-pyrazolo[4,3-c]quinolin-3(5h)-one
F3406-4901
unii-86pwq4pvn0
2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3h)-one
86pwq4pvn0 ,
3h-pyrazolo(4,3-c)quinolin-3-one, 2-(4-chlorophenyl)-2,5-dihydro-
2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinolin-3(3h)-one
AKOS021973584
SCHEMBL7308514
CQINXWYVIOMBEI-UHFFFAOYSA-N
2-(p-chlorophenyl)-pyrazolo[4,3-c]quinolin-3(5h)-one
2-(p-chlorophenyl)-pyrazolo[4, 3-c]quinolin-3(5h)-one
2-(p-chlorophenyl)-pyrazolo-[4,3-c]quinolin-3(5h)-one
2-(4-chlorophenyl)-2h,3h,5h-pyrazolo[4,3-c]quinolin-3-one
SCHEMBL17236324
2-(p-chlorophenyl)pyrazolo[4,3-c]quinoline-3(5h)-one
Q5010990
DTXSID20998970
PD159704

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The intravenous pharmacokinetic disposition of the novel, atypical anxiolytic CGS 9896 was studied in six cynomolgus monkeys."( Pharmacokinetic disposition of the novel atypical anxiolytic CGS 9896 in the cynomolgus monkey.
Honc, F; Kochak, GM; Mahoney, CJ; Rakhit, A, 1988
)
0.27
" The method is applied to a pharmacokinetic study of CGS-8216 in the rat."( A pharmacokinetic study of CGS-8216, a benzodiazepine receptor ligand, in the rat.
File, SE; Greenblatt, DJ; Lister, RG, 1984
)
0.27

Dosage Studied

ExcerptRelevanceReference
" Following a four week dosing period with 30 mg/kg of either CGS 9896 or diazepam, the drugs were withdrawn and similar behavioral measures obtained at various withdrawal intervals up to 15 days."( Lack of tolerance or withdrawal effects in mice after chronic administration of the non-sedating anxiolytic, CGS 9896.
Boast, CA; Gerhardt, SC, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-199036 (66.67)18.7374
1990's15 (27.78)18.2507
2000's0 (0.00)29.6817
2010's2 (3.70)24.3611
2020's1 (1.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.15 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]